Amy Or, Wall Street Journal, 17 December 2014
Norwest Venture Partners’ portfolio company iCardiac Technologies Inc. may have a way to help pharmaceutical companies detect which experimental drugs might flat line over cardiac concerns.
The Rochester, N.Y.-based company recently completed a study in collaboration with the U.S. Food and Drug Administration which demonstrated that cardiac toxicity in drugs can be detected much earlier in the development process than previously thought by medical professionals.